AU2001295503A1 - Composition for the elimination of autoreactive b-cells - Google Patents
Composition for the elimination of autoreactive b-cellsInfo
- Publication number
- AU2001295503A1 AU2001295503A1 AU2001295503A AU9550301A AU2001295503A1 AU 2001295503 A1 AU2001295503 A1 AU 2001295503A1 AU 2001295503 A AU2001295503 A AU 2001295503A AU 9550301 A AU9550301 A AU 9550301A AU 2001295503 A1 AU2001295503 A1 AU 2001295503A1
- Authority
- AU
- Australia
- Prior art keywords
- autoreactive
- elimination
- cells
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000008030 elimination Effects 0.000 title 1
- 238000003379 elimination reaction Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Rheumatology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00117354.1 | 2000-08-22 | ||
| EP00117354 | 2000-08-22 | ||
| PCT/EP2001/009714 WO2002016414A2 (en) | 2000-08-22 | 2001-08-22 | Composition for the elimination of autoreactive b-cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2001295503A1 true AU2001295503A1 (en) | 2002-03-04 |
Family
ID=8169503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001295503A Abandoned AU2001295503A1 (en) | 2000-08-22 | 2001-08-22 | Composition for the elimination of autoreactive b-cells |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US7332168B2 (en) |
| EP (1) | EP1311549A2 (en) |
| AU (1) | AU2001295503A1 (en) |
| WO (1) | WO2002016414A2 (en) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| US7541184B2 (en) | 2000-02-24 | 2009-06-02 | Invitrogen Corporation | Activation and expansion of cells |
| EP1474451A2 (en) | 2002-02-13 | 2004-11-10 | Micromet AG | De-immunized (poly)peptide constructs |
| US20050084967A1 (en) | 2002-06-28 | 2005-04-21 | Xcyte Therapies, Inc. | Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation |
| US20040175373A1 (en) * | 2002-06-28 | 2004-09-09 | Xcyte Therapies, Inc. | Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation |
| WO2004031767A2 (en) * | 2002-10-03 | 2004-04-15 | The Hospital For Sick Children Research Institute | Prevention of primary sjögren’s syndrome by ica69 deficiency |
| CA2522586C (en) | 2003-05-31 | 2017-02-21 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders |
| AR049292A1 (en) * | 2004-06-04 | 2006-07-12 | Genentech Inc | METHOD TO TREAT LUPUS WITH A CD20 ANTIBODY |
| WO2005117978A2 (en) * | 2004-06-04 | 2005-12-15 | Genentech, Inc. | Method for treating multiple sclerosis |
| AR073295A1 (en) | 2008-09-16 | 2010-10-28 | Genentech Inc | METHODS TO TREAT PROGRESSIVE MULTIPLE SCLEROSIS. MANUFACTURING ARTICLE. |
| US20110189178A1 (en) * | 2010-02-04 | 2011-08-04 | Xencor, Inc. | Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions |
| WO2011101870A1 (en) * | 2010-02-22 | 2011-08-25 | Transgene Biotek Ltd. | Fusion proteins for the treatment of multiple sclerosis and other autoimmune diseases |
| BR112013011842A2 (en) | 2010-11-12 | 2016-08-16 | Getts Consulting And Project Man | modified immunomodulatory particles |
| KR102283760B1 (en) | 2012-06-21 | 2021-08-03 | 노쓰웨스턴유니버시티 | Peptide conjugated particles |
| US20140004121A1 (en) | 2012-06-27 | 2014-01-02 | Amgen Inc. | Anti-mesothelin binding proteins |
| EP4406597A3 (en) | 2013-03-13 | 2024-11-13 | onCOUR Pharma, Inc. | Immune-modifying particles for the treatment of inflammation |
| JP6553033B2 (en) | 2013-08-13 | 2019-07-31 | ノースウェスタン ユニバーシティ | Peptide conjugate particle |
| US9765142B2 (en) | 2013-10-11 | 2017-09-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | TEM8 antibodies and their use in treatment and detection of tumors |
| WO2015103549A1 (en) | 2014-01-03 | 2015-07-09 | The United States Of America, As Represented By The Secretary Department Of Health And Human Services | Neutralizing antibodies to hiv-1 env and their use |
| CA2940579A1 (en) | 2014-03-13 | 2015-09-17 | Universitaet Basel | Carbohydrate ligands that bind to igm antibodies against myelin-associated glycoprotein |
| US10301370B2 (en) | 2014-05-02 | 2019-05-28 | The Trustees Of The University Of Pennsylvania | Compositions and methods of chimeric autoantibody receptor T cells |
| US10160795B2 (en) | 2014-11-14 | 2018-12-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to Ebola virus glycoprotein and their use |
| EP3261665A1 (en) | 2015-02-24 | 2018-01-03 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use |
| PL3271389T3 (en) | 2015-03-20 | 2020-08-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to gp120 and their use |
| WO2017046172A1 (en) | 2015-09-16 | 2017-03-23 | Universität Basel | Carbohydrate ligands that bind to antibodies against glycoepitopes of glycosphingolipids |
| CA2997809A1 (en) | 2015-10-07 | 2017-04-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Il-7r-alpha specific antibodies for treating acute lymphoblastic leukemia |
| EP3371214A1 (en) | 2015-11-03 | 2018-09-12 | THE UNITED STATES OF AMERICA, represented by the S | Neutralizing antibodies to hiv-1 gp41 and their use |
| WO2017192589A1 (en) | 2016-05-02 | 2017-11-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to influenza ha and their use and identification |
| CA3045797A1 (en) * | 2016-12-02 | 2018-06-07 | The Texas A&M University System | Fusion proteins for selectively depleting antigen-specific antibodies |
| US11021535B2 (en) | 2017-02-10 | 2021-06-01 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use |
| WO2019136029A1 (en) | 2018-01-02 | 2019-07-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to ebola virus glycoprotein and their use |
| EP3755713A1 (en) | 2018-02-21 | 2020-12-30 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Neutralizing antibodies to hiv-1 env and their use |
| WO2020132214A2 (en) | 2018-12-20 | 2020-06-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof |
| US12269872B2 (en) | 2019-05-03 | 2025-04-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to Plasmodium falciparum circumsporozoite protein and their use |
| BR112021022682A2 (en) | 2019-05-14 | 2022-02-22 | Provention Bio Inc | Methods and compositions for preventing type 1 diabetes |
| US20230085439A1 (en) | 2019-05-21 | 2023-03-16 | University Of Georgia Research Foundation, Inc. | Antibodies that bind human metapneumovirus fusion protein and their use |
| CA3142833A1 (en) | 2019-07-02 | 2021-01-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies that bind egfrviii and their use |
| US12006366B2 (en) | 2020-06-11 | 2024-06-11 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| WO2022132904A1 (en) | 2020-12-17 | 2022-06-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies targeting sars-cov-2 |
| CN117642178A (en) | 2021-02-09 | 2024-03-01 | 美国政府(由卫生和人类服务部的部长所代表) | Antibodies targeting coronavirus spike protein |
| US20240117019A1 (en) | 2021-02-09 | 2024-04-11 | University Of Georgia Research Foundation, Inc. | Human monoclonal antibodies against pneumococcal antigens |
| US20240401239A1 (en) | 2021-09-17 | 2024-12-05 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Synthetic humanized llama nanobody library and use thereof to identify sars-cov-2 neutralizing antibodies |
| WO2023114847A2 (en) | 2021-12-14 | 2023-06-22 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating disease |
| JP2025506172A (en) | 2022-02-10 | 2025-03-07 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | Broadly targeted human monoclonal antibodies against coronaviruses |
| WO2023192881A1 (en) | 2022-03-28 | 2023-10-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to hiv-1 env and their use |
| EP4565329A1 (en) | 2022-08-01 | 2025-06-11 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Monoclonal antibodies that bind to the underside of influenza viral neuraminidase |
| WO2024054822A1 (en) | 2022-09-07 | 2024-03-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Engineered sars-cov-2 antibodies with increased neutralization breadth |
| WO2024064826A1 (en) | 2022-09-22 | 2024-03-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use |
| EP4638491A1 (en) | 2022-12-19 | 2025-10-29 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Monoclonal antibodies for treating sars-cov-2 infection |
| WO2024138151A1 (en) | 2022-12-22 | 2024-06-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Ebolavirus (sudan and zaire) antibodies from non-human primates and human vaccinees |
| WO2024243355A1 (en) | 2023-05-24 | 2024-11-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies that target the rh5 complex of blood-stage plasmodium falciparum |
| WO2025014896A1 (en) | 2023-07-07 | 2025-01-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Humanized 40h3 antibody |
| WO2025024233A1 (en) | 2023-07-21 | 2025-01-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bispecific antibodies that broadly target coronaviruses |
| WO2025106427A1 (en) | 2023-11-14 | 2025-05-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing and protective monoclonal antibodies against respiratory syncytial virus (rsv) |
| WO2025117384A1 (en) | 2023-12-01 | 2025-06-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Broadly neutralizing influenza hemagglutinin stem-directed antibodies |
| WO2025137284A2 (en) | 2023-12-21 | 2025-06-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Broadly neutralizing antibodies against sars-cov-2 and sars-cov variants |
| EP4574842A1 (en) | 2023-12-22 | 2025-06-25 | Deutsches Rheuma-Forschungszentrum Berlin | Bispecific conjugate for antigen-specific b cell depletion by t cells |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5614611A (en) * | 1987-12-31 | 1997-03-25 | Tanox Biosystems, Inc. | Humanized monoclonal antibodies binding to IgE-bearing B cells but not basophils |
| DE68929402T2 (en) * | 1988-12-22 | 2002-12-05 | Genentech, Inc. | METHOD FOR PRODUCING WATER-SOLUBLE POLYPEPTIDES |
| US5225538A (en) * | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
| WO1995007096A1 (en) * | 1993-09-06 | 1995-03-16 | La Trobe University | Treatment of autoimmune disease |
| US5968768A (en) | 1993-11-02 | 1999-10-19 | Duke University | CD6 ligand encoding sequence |
| CA2183268C (en) * | 1994-03-07 | 2001-05-15 | Edward D. Ball | Bispecific molecules having clinical utilities |
| AU7010996A (en) * | 1995-08-30 | 1997-03-19 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Selective elimination of t cells that recognize specific preselected targets |
| JPH0977800A (en) | 1995-09-12 | 1997-03-25 | Takeji Nishikawa | Fused protein, and therapeutic medicine, therapeutic apparatus and diagnostic agent for fallen leaf-like pemphigus and measurement of antibody |
| WO1998033912A1 (en) * | 1997-01-30 | 1998-08-06 | Human Genome Sciences, Inc. | MYELIN OLIGODENDROCYTE GLYCOPROTEIN-LIKE PROTEIN (MOGp) AND METHODS OF USE |
| DE69836197T2 (en) | 1997-08-29 | 2007-09-06 | Innogenetics N.V. | METHYLATED SMD HOMOLOGOUS PEPTIDES THAT RESPOND WITH ANTIBODIES FROM SERA OF LIVING WITH SYSTEMIC LUPUS ERYTHEMATODES |
| ZA9810133B (en) | 1997-11-07 | 1999-05-17 | Biogen Inc | BMOG a novel protein member of the myelin-oligodendrocyte glycoprotein family and its use for ummonomodulatory purposes |
| CA2318068A1 (en) | 1998-02-11 | 1999-08-19 | The Regents Of The University Of California | Podocalyxin like sialomucins having selectin ligand activity |
| CA2331771A1 (en) | 1998-07-06 | 2000-01-13 | The University Of Tennessee Research Corporation | Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors |
| US6197294B1 (en) * | 1998-10-26 | 2001-03-06 | Neurotech S.A. | Cell surface molecule-induced macrophage activation |
| US6569431B2 (en) * | 2000-10-17 | 2003-05-27 | The Regents Of The University Of California | Recombinant antibody fragments as autoantibody antagonists |
-
2001
- 2001-08-22 WO PCT/EP2001/009714 patent/WO2002016414A2/en not_active Ceased
- 2001-08-22 EP EP01976136A patent/EP1311549A2/en not_active Withdrawn
- 2001-08-22 US US10/362,591 patent/US7332168B2/en not_active Expired - Fee Related
- 2001-08-22 AU AU2001295503A patent/AU2001295503A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002016414A3 (en) | 2002-11-07 |
| WO2002016414A2 (en) | 2002-02-28 |
| US7332168B2 (en) | 2008-02-19 |
| US20040072749A1 (en) | 2004-04-15 |
| EP1311549A2 (en) | 2003-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001295503A1 (en) | Composition for the elimination of autoreactive b-cells | |
| AU781269C (en) | Pharmaceutical compositions | |
| AU2001272849A1 (en) | Composition for the treatment of osteoarthritis | |
| AU2001252574A1 (en) | Novel bicyclic compounds | |
| AU2002363361A1 (en) | Pharmaceutical compositions containing oxybutynin | |
| AU2002323381A1 (en) | Deodorant composition | |
| AU2001274307A1 (en) | Pharmaceutical compositions | |
| AU2002229140A1 (en) | Controlled release pharmaceutical composition | |
| AU2001272852A1 (en) | Composition for the treatment of migraine | |
| AU2000276362A1 (en) | Composition for the treatment of diabetes | |
| AU2001263839A1 (en) | Liquid formulations | |
| AUPQ875700A0 (en) | Combination compositions | |
| AU2002214324A1 (en) | Medicinal compositions | |
| AU2001290239A1 (en) | Medicinal composition | |
| AU2002217071A1 (en) | Novel use of polyhydroxy compounds | |
| AU2001273919A1 (en) | Pharmaceutical compositions | |
| AU2001241098A1 (en) | Composition | |
| AU4085201A (en) | Pharmaceutical composition | |
| AU2001275201A1 (en) | Acne-treating composition | |
| AU2001267541A1 (en) | Vaccine composition | |
| AU3586401A (en) | Pharmaceutical composition | |
| AU2001292578A1 (en) | Pharmaceutical compounds | |
| AU2002354460A1 (en) | Medicinal composition | |
| AU2001287732A1 (en) | Copolycarbonate-based composition | |
| AU2001282541A1 (en) | Medicinal compositions |